Cardinal Health Inc. (CAH - Free Report) is a healthcare services company engaged in providing pharmaceutical and medical products and services in the United States and International markets. The company primarily operates in two segments, Pharmaceutical and Medical.
Currently, Cardinal Health has a Zacks Rank #4 (Sell) but that could change following its fourth-quarter fiscal 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Cardinal Health’s adjusted earnings surged 14% on a year-over-year basis to $1.14 per share. It also managed to outpace the Zacks Consensus Estimate of $1.13.
Revenues: Revenues increased 14% on a year-over-year basis to $31.38 billion. It also managed to beat the Zacks Consensus Estimate of $30.67 billion.
Key Stats: Pharmaceutical revenues surged 14% to $28.18 billion while revenues from Medical segment increased 12% to $3.21 billion in the quarter.
Major Factors: Pharmaceutical segment revenues increased due to strong growth from existing and net new distribution customers. Strong performance from the Specialty business also drove results. Higher contributions from acquisitions and strong growth from Cardinal Health brand products were primarily responsible for the growth in Medical segment revenues.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Cardinal Health earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Cardinal Health Inc. (CAH - Free Report) is a healthcare services company engaged in providing pharmaceutical and medical products and services in the United States and International markets. The company primarily operates in two segments, Pharmaceutical and Medical.
Currently, Cardinal Health has a Zacks Rank #4 (Sell) but that could change following its fourth-quarter fiscal 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Cardinal Health’s adjusted earnings surged 14% on a year-over-year basis to $1.14 per share. It also managed to outpace the Zacks Consensus Estimate of $1.13.
Revenues: Revenues increased 14% on a year-over-year basis to $31.38 billion. It also managed to beat the Zacks Consensus Estimate of $30.67 billion.
Key Stats: Pharmaceutical revenues surged 14% to $28.18 billion while revenues from Medical segment increased 12% to $3.21 billion in the quarter.
Major Factors: Pharmaceutical segment revenues increased due to strong growth from existing and net new distribution customers. Strong performance from the Specialty business also drove results. Higher contributions from acquisitions and strong growth from Cardinal Health brand products were primarily responsible for the growth in Medical segment revenues.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Cardinal Health earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on CAH - FREE